{"id":3938,"date":"2015-01-14T14:27:28","date_gmt":"2015-01-14T05:27:28","guid":{"rendered":"http:\/\/dna1.dna.rbrc.jp\/en\/?page_id=3938"},"modified":"2023-06-13T09:49:42","modified_gmt":"2023-06-13T00:49:42","slug":"gsb0020en","status":"publish","type":"page","link":"http:\/\/dna.brc.riken.jp\/en\/gsb0000en\/gsb0020en","title":{"rendered":"p53, p63 and p73"},"content":{"rendered":"

<\/a><\/p>\n

p53, p63 and p73<\/h2>\n
\n

Page top<\/a> | Reporter clone<\/a> | p53 status<\/a> | p53 mutant<\/a><\/p>\n<\/div>\n

Human gene resources<\/h3>\n\n\n\n\n\n\n
Locus<\/th>\nGene Products<\/th>\nAlternative Name<\/th>\n<\/tr>\n
TP53<\/a><\/td>\ntumor protein p53<\/td>\nFLJ92943; LFS1; P53; TRP53<\/td>\n<\/tr>\n
TP63<\/a><\/td>\ntumor protein p63<\/td>\nAIS; B(p51A); B(p51B); EEC3; KET; LMS; NBP; OFC8; RHS; SHFM4; TP53CP; TP53L; TP73L; p40; p51; p53CP; p63; p73H; p73L<\/td>\n<\/tr>\n
TP73<\/a><\/td>\ntumor protein p73<\/td>\nP73<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Mouse gne resources<\/h3>\n\n\n\n\n
Locus<\/th>\nGene Products<\/th>\nAlternative Name<\/th>\n<\/tr>\n
Trp53<\/a><\/td>\ntransformation related protein 53<\/td>\nTp53|bbl|bfy|bhy|p44|p53<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

\n

Target genes<\/h2>\n

Human genevresources<\/h3>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Locus<\/th>\nGene Products<\/th>\nAlternative Name<\/th>\n<\/tr>\n
ABCB1<\/a><\/td>\nATP-binding cassette, sub-family B (MDR\/TAP), member 1<\/td>\nABC20; CD243; CLCS; GP170; MDR1; MGC163296; P-GP; PGY1<\/td>\n<\/tr>\n
ABCC1<\/a><\/td>\nATP-binding cassette, sub-family C (CFTR\/MRP), member 1<\/td>\nABC29; ABCC; DKFZp686N04233; DKFZp781G125; GS-X; MRP; MRP1<\/td>\n<\/tr>\n
AKT1<\/a><\/td>\nv-akt murine thymoma viral oncogene homolog 1<\/td>\nAKT; MGC99656; PKB; PKB-ALPHA; PRKBA; RAC; RAC-ALPHA<\/td>\n<\/tr>\n
AIFM2<\/a><\/td>\napoptosis-inducing factor, mitochondrion-associated, 2<\/td>\nAMID; DKFZp686L1298; PRG3; RP11-367H5.2<\/td>\n<\/tr>\n
ANTXR1<\/a><\/td>\nanthrax toxin receptor 1<\/td>\nATR; FLJ10601; FLJ11298; FLJ21776; TEM8<\/td>\n<\/tr>\n
APAF1<\/a><\/td>\napoptotic peptidase activating factor 1<\/td>\nAPAF-1; CED4; DKFZp781B1145<\/td>\n<\/tr>\n
APCS<\/a><\/td>\namyloid P component, serum<\/td>\nMGC88159; PTX2; SAP<\/td>\n<\/tr>\n
AQP1<\/a><\/td>\naquaporin 1 (Colton blood group)<\/td>\nAQP-CHIP; CHIP28; CO; MGC26324<\/td>\n<\/tr>\n
ATR<\/a><\/td>\nataxia telangiectasia and Rad3 related<\/td>\nFRP1; MEC1; SCKL; SCKL1<\/td>\n<\/tr>\n
BAI1<\/a><\/td>\nbrain-specific angiogenesis inhibitor 1<\/td>\nFLJ41988; GDAIF<\/td>\n<\/tr>\n
BAI2<\/a><\/td>\nbrain-specific angiogenesis inhibitor 2<\/td>\nBAI2<\/td>\n<\/tr>\n
BAK1<\/a><\/td>\nBCL2-antagonist\/killer 1<\/td>\nBAK; BAK-LIKE; BCL2L7; CDN1; MGC117255; MGC3887<\/td>\n<\/tr>\n
BAX<\/a><\/td>\nBCL2-associated X protein<\/td>\nBCL2L4<\/td>\n<\/tr>\n
BBC3<\/a><\/td>\nBCL2 binding component 3<\/td>\nFLJ42994; JFY-1; JFY1; PUMA<\/td>\n<\/tr>\n
BCL2<\/a><\/td>\nB-cell CLL\/lymphoma 2<\/td>\nBcl-2<\/td>\n<\/tr>\n
BCL2L1<\/a><\/td>\nBCL2-like 1<\/td>\nBCL-XL\/S; BCL2L; BCLX; BCLXL; BCLXS; Bcl-X; DKFZp781P2092; bcl-xL; bcl-xS<\/td>\n<\/tr>\n
BCL3<\/a><\/td>\nB-cell CLL\/lymphoma 3<\/td>\nBCL4; D19S37<\/td>\n<\/tr>\n
BIRC5<\/a><\/td>\nbaculoviral IAP repeat containing 5<\/td>\nAPI4; EPR-1<\/td>\n<\/tr>\n
RNGTT<\/a><\/td>\nRNA guanylyltransferase and 5′-phosphatase<\/td>\nCAP1A; DKFZp686J2031; HCE; HCE1; hCAP<\/td>\n<\/tr>\n
TP53TG5<\/a><\/td>\nTP53 target 5<\/td>\nC20orf10; CLG01<\/td>\n<\/tr>\n
CABLES1<\/a><\/td>\nCdk5 and Abl enzyme substrate 1<\/td>\nCABL1; CABLES; FLJ35924; HsT2563; IK3-1<\/td>\n<\/tr>\n
CASP1<\/a><\/td>\ncaspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase)<\/td>\nICE; IL1BC; P45<\/td>\n<\/tr>\n
CAV1<\/a><\/td>\ncaveolin 1, caveolae protein, 22kDa<\/td>\nBSCL3; CGL3; MSTP085; VIP21<\/td>\n<\/tr>\n
CCND1<\/a><\/td>\ncyclin D1<\/td>\nBCL1; D11S287E; PRAD1; U21B31<\/td>\n<\/tr>\n
CHEK1<\/a><\/td>\nCHK1 checkpoint homolog (S. pombe)<\/td>\nCHK1<\/td>\n<\/tr>\n
CHEK2<\/a><\/td>\nCHK2 checkpoint homolog (S. pombe)<\/td>\nCDS1; CHK2; HuCds1; LFS2; PP1425; RAD53<\/td>\n<\/tr>\n
CHUK<\/a><\/td>\nconserved helix-loop-helix ubiquitous kinase<\/td>\nIKBKA; IKK-alpha; IKK1; IKKA; NFKBIKA; TCF16<\/td>\n<\/tr>\n
CTNNB1<\/a><\/td>\ncatenin (cadherin-associated protein), beta 1, 88kDa<\/td>\nCTNNB; DKFZp686D02253; FLJ25606; FLJ37923<\/td>\n<\/tr>\n
CX3CL1<\/a><\/td>\nchemokine (C-X3-C motif) ligand 1<\/td>\nABCD-3; C3Xkine; CXC3; CXC3C; NTN; NTT; SCYD1; fractalkine; neurotactin<\/td>\n<\/tr>\n
DDB2<\/a><\/td>\ndamage-specific DNA binding protein 2, 48kDa<\/td>\nDDBB; FLJ34321; UV-DDB2<\/td>\n<\/tr>\n
DKK1<\/a><\/td>\ndickkopf homolog 1 (Xenopus laevis)<\/td>\nDKK-1; SK<\/td>\n<\/tr>\n
DUSP1<\/a><\/td>\ndual specificity phosphatase 1<\/td>\nCL100; HVH1; MKP-1; MKP1; PTPN10<\/td>\n<\/tr>\n
DUSP12<\/a><\/td>\ndual specificity phosphatase 12<\/td>\nDUSP1; YVH1<\/td>\n<\/tr>\n
EGFR<\/a><\/td>\nepidermal growth factor receptor<\/td>\nERBB; ERBB1; HER1; PIG61; mENA<\/td>\n<\/tr>\n
EGR1<\/a><\/td>\nearly growth response 1<\/td>\nAT225; G0S30; KROX-24; NGFI-A; TIS8; ZIF-268; ZNF225<\/td>\n<\/tr>\n
EPHA2<\/a><\/td>\nEPH receptor A2<\/td>\nARCC2; ECK<\/td>\n<\/tr>\n
ERBB2<\/a><\/td>\nv-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro\/glioblastoma derived oncogene homolog (avian)<\/td>\nCD340; HER-2; HER-2\/neu; HER2; MLN 19; NEU; NGL; TKR1<\/td>\n<\/tr>\n
EZH2<\/a><\/td>\nenhancer of zeste homolog 2 (Drosophila)<\/td>\nENX-1; ENX1; EZH1; KMT6; KMT6A; MGC9169<\/td>\n<\/tr>\n
FAS<\/a><\/td>\nFas (TNF receptor superfamily, member 6)<\/td>\nALPS1A; APO-1; APT1; CD95; FAS1; FASTM; TNFRSF6<\/td>\n<\/tr>\n
FDXR<\/a><\/td>\nferredoxin reductase<\/td>\nADXR<\/td>\n<\/tr>\n
GADD45A<\/a><\/td>\ngrowth arrest and DNA-damage-inducible, alpha<\/td>\nDDIT1; GADD45<\/td>\n<\/tr>\n
GML<\/a><\/td>\nglycosylphosphatidylinositol anchored molecule like protein<\/td>\nLY6DL<\/td>\n<\/tr>\n
HRAS<\/a><\/td>\nv-Ha-ras Harvey rat sarcoma viral oncogene homolog<\/td>\nC-BAS\/HAS; C-H-RAS; C-HA-RAS1; CTLO; H-RASIDX; HAMSV; HRAS1; K-RAS; N-RAS; RASH1<\/td>\n<\/tr>\n
IFI16<\/a><\/td>\ninterferon, gamma-inducible protein 16<\/td>\nIFNGIP1; MGC9466; PYHIN2<\/td>\n<\/tr>\n
IGFBP3<\/a><\/td>\ninsulin-like growth factor binding protein 3<\/td>\nBP-53; IBP3<\/td>\n<\/tr>\n
IL8<\/a><\/td>\ninterleukin 8<\/td>\nCXCL8; GCP-1; GCP1; LECT; LUCT; LYNAP; MDNCF; MONAP; NAF; NAP-1; NAP1<\/td>\n<\/tr>\n
MKI67<\/a><\/td>\nantigen identified by monoclonal antibody Ki-67<\/td>\nKIA<\/td>\n<\/tr>\n
KLK3<\/a><\/td>\nkallikrein-related peptidase 3<\/td>\nAPS; KLK2A1; PSA; hK3<\/td>\n<\/tr>\n
KLKB1<\/a><\/td>\nkallikrein B, plasma (Fletcher factor) 1<\/td>\nKLK3; PPK<\/td>\n<\/tr>\n
MAD1L1<\/a><\/td>\nMAD1 mitotic arrest deficient-like 1 (yeast)<\/td>\nMAD1; PIG9; TP53I9; TXBP181<\/td>\n<\/tr>\n
MDM2<\/a><\/td>\nMdm2 p53 binding protein homolog (mouse)<\/td>\nHDMX; MGC5370; MGC71221; hdm2<\/td>\n<\/tr>\n
TNFRSF10C<\/a><\/td>\ntumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain<\/td>\nCD263; DCR1; DCR1-TNFR; LIT; MGC149501; MGC149502; TRAIL-R3; TRAILR3; TRID<\/td>\n<\/tr>\n
MMAB<\/a><\/td>\nmethylmalonic aciduria (cobalamin deficiency) cblB type<\/td>\nATR; MGC20496; cblB; cob<\/td>\n<\/tr>\n
MMP2<\/a><\/td>\nmatrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)<\/td>\nCLG4; CLG4A; MMP-II; MONA; TBE-1<\/td>\n<\/tr>\n
MSH2<\/a><\/td>\nmutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)<\/td>\nCOCA1; FCC1; HNPCC; HNPCC1; LCFS2<\/td>\n<\/tr>\n
MYC<\/a><\/td>\nv-myc myelocytomatosis viral oncogene homolog (avian)<\/td>\nMRTL; bHLHe39; c-Myc<\/td>\n<\/tr>\n
NFATC4<\/a><\/td>\nnuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4<\/td>\nNF-ATc4; NFAT3<\/td>\n<\/tr>\n
NFIC<\/a><\/td>\nnuclear factor I\/C (CCAAT-binding transcription factor)<\/td>\nCTF; CTF5; MGC20153; NF-I; NFI<\/td>\n<\/tr>\n
NLRC4<\/a><\/td>\nNLR family, CARD domain containing 4<\/td>\nCARD12; CLAN; CLAN1; CLANA; CLANB; CLANC; CLAND; CLR2.1; IPAF<\/td>\n<\/tr>\n
NME1<\/a><\/td>\nnon-metastatic cells 1, protein (NM23A) expressed in<\/td>\nAWD; GAAD; NB; NBS; NDKA; NDPK-A; NDPKA; NM23; NM23-H1<\/td>\n<\/tr>\n
NOL3<\/a><\/td>\nnucleolar protein 3 (apoptosis repressor with CARD domain)<\/td>\nARC; FLJ35304; MYP; NOP; NOP30<\/td>\n<\/tr>\n
NOS2<\/a><\/td>\nnitric oxide synthase 2, inducible<\/td>\nHEP-NOS; INOS; NOS; NOS2A<\/td>\n<\/tr>\n
NTHL1<\/a><\/td>\nnth endonuclease III-like 1 (E. coli)<\/td>\nNTH1; OCTS3<\/td>\n<\/tr>\n
PCNA<\/a><\/td>\nproliferating cell nuclear antigen<\/td>\nMGC8367<\/td>\n<\/tr>\n
PIAS3<\/a><\/td>\nprotein inhibitor of activated STAT, 3<\/td>\nFLJ14651; ZMIZ5<\/td>\n<\/tr>\n
PLK1<\/a><\/td>\npolo-like kinase 1<\/td>\nPLK; STPK13<\/td>\n<\/tr>\n
PLK3<\/a><\/td>\npolo-like kinase 3<\/td>\nCNK; FNK; PRK<\/td>\n<\/tr>\n
PMAIP1<\/a><\/td>\nphorbol-12-myristate-13-acetate-induced protein 1<\/td>\nAPR; NOXA<\/td>\n<\/tr>\n
PML<\/a><\/td>\npromyelocytic leukemia<\/td>\nMYL; PP8675; RNF71; TRIM19<\/td>\n<\/tr>\n
POLD1<\/a><\/td>\npolymerase (DNA directed), delta 1, catalytic subunit 125kDa<\/td>\nCDC2; POLD<\/td>\n<\/tr>\n
PRKAB1<\/a><\/td>\nprotein kinase, AMP-activated, beta 1 non-catalytic subunit<\/td>\nAMPK; HAMPKb; MGC17785<\/td>\n<\/tr>\n
PTEN<\/a><\/td>\nphosphatase and tensin homolog<\/td>\n10q23del; BZS; DEC; GLM2; MGC11227; MHAM; MMAC1; PTEN1; TEP1<\/td>\n<\/tr>\n
PTTG1<\/a><\/td>\npituitary tumor-transforming 1<\/td>\nEAP1; HPTTG; MGC126883; MGC138276; PTTG; TUTR1<\/td>\n<\/tr>\n
RB1<\/a><\/td>\nretinoblastoma 1<\/td>\nOSRC; RB; p105-Rb; pRb; pp110<\/td>\n<\/tr>\n
RELA<\/a><\/td>\nv-rel reticuloendotheliosis viral oncogene homolog A (avian)<\/td>\nMGC131774; NFKB3; p65<\/td>\n<\/tr>\n
RHOA<\/a><\/td>\nras homolog gene family, member A<\/td>\nARH12; ARHA; RHO12; RHOH12<\/td>\n<\/tr>\n
RRM2B<\/a><\/td>\nribonucleotide reductase M2 B (TP53 inducible)<\/td>\nDKFZp686M05248; MGC102856; MGC42116; MTDPS8A; MTDPS8B; P53R2<\/td>\n<\/tr>\n
S100B<\/a><\/td>\nS100 calcium binding protein B<\/td>\nNEF; S100; S100-B; S100beta<\/td>\n<\/tr>\n
SIVA1<\/a><\/td>\nSIVA1, apoptosis-inducing factor<\/td>\nCD27BP; SIVA; Siva-1; Siva-2<\/td>\n<\/tr>\n
SSTR2<\/a><\/td>\nsomatostatin receptor 2<\/td>\nSSTR2<\/td>\n<\/tr>\n
STAT1<\/a><\/td>\nsignal transducer and activator of transcription 1, 91kDa<\/td>\nCANDF7; DKFZp686B04100; ISGF-3; STAT91<\/td>\n<\/tr>\n
STAT3<\/a><\/td>\nsignal transducer and activator of transcription 3 (acute-phase response factor)<\/td>\nAPRF; FLJ20882; HIES; MGC16063<\/td>\n<\/tr>\n
EPCAM<\/a><\/td>\nepithelial cell adhesion molecule<\/td>\nDIAR5; EGP-2; EGP314; EGP40; ESA; GA733-2; HNPCC8; KS1\/4; KSA; M4S1; MIC18; MK-1; TACSTD1; TROP1<\/td>\n<\/tr>\n
TBXAS1<\/a><\/td>\nthromboxane A synthase 1 (platelet)<\/td>\nBDPLT14; CYP5; CYP5A1; FLJ52771; GHOSAL; THAS; TS; TXAS; TXS<\/td>\n<\/tr>\n
TERT<\/a><\/td>\ntelomerase reverse transcriptase<\/td>\nDKCA2; DKCB4; EST2; TCS1; TP2; TRT; hEST2; hTRT<\/td>\n<\/tr>\n
TGFA<\/a><\/td>\ntransforming growth factor, alpha<\/td>\nTFGA<\/td>\n<\/tr>\n
TNFRSF10A<\/a><\/td>\ntumor necrosis factor receptor superfamily, member 10a<\/td>\nAPO2; CD261; DR4; MGC9365; TRAILR-1; TRAILR1<\/td>\n<\/tr>\n
TNFRSF10B<\/a><\/td>\ntumor necrosis factor receptor superfamily, member 10b<\/td>\nCD262; DR5; KILLER; KILLER\/DR5; TRAIL-R2; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; ZTNFR9<\/td>\n<\/tr>\n
TP53<\/a><\/td>\ntumor protein p53<\/td>\nFLJ92943; LFS1; P53; TRP53<\/td>\n<\/tr>\n
TP53I3<\/a><\/td>\ntumor protein p53 inducible protein 3<\/td>\nPIG3<\/td>\n<\/tr>\n
TP73<\/a><\/td>\ntumor protein p73<\/td>\nP73<\/td>\n<\/tr>\n
TP63<\/a><\/td>\ntumor protein p63<\/td>\nAIS; B(p51A); B(p51B); EEC3; KET; LMS; NBP; OFC8; RHS; SHFM4; TP53CP; TP53L; TP73L; p40; p51; p53CP; p63; p73H; p73L<\/td>\n<\/tr>\n
TRIM22<\/a><\/td>\ntripartite motif containing 22<\/td>\nGPSTAF50; RNF94; STAF50<\/td>\n<\/tr>\n
TYMS<\/a><\/td>\nthymidylate synthetase<\/td>\nHST422; MGC88736; TMS; TS<\/td>\n<\/tr>\n
UNC5B<\/a><\/td>\nunc-5 homolog B (C. elegans)<\/td>\nUNC5H2; p53RDL1<\/td>\n<\/tr>\n
VEGFA<\/a><\/td>\nvascular endothelial growth factor A<\/td>\nMGC70609; MVCD1; VEGF; VPF<\/td>\n<\/tr>\n
WRN<\/a><\/td>\nWerner syndrome, RecQ helicase-like<\/td>\nDKFZp686C2056; RECQ3; RECQL2; RECQL3<\/td>\n<\/tr>\n
XPC<\/a><\/td>\nxeroderma pigmentosum, complementation group C<\/td>\nRAD4; XP3; XPCC<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Mouse gene resources<\/h3>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Locus<\/th>\nGene Products<\/th>\nAlternative Name<\/th>\n<\/tr>\n
Abcb1b<\/a><\/td>\nATP-binding cassette, sub-family B (MDR\/TAP), member 1B<\/td>\nAbcb1|Mdr1|Mdr1b|Pgy-1|Pgy1|mdr<\/td>\n<\/tr>\n
Abcc1<\/a><\/td>\nATP-binding cassette, sub-family C (CFTR\/MRP), member 1<\/td>\nAbcc1a|Abcc1b|MRP|Mdrap|Mrp1<\/td>\n<\/tr>\n
Akt1<\/a><\/td>\nthymoma viral proto-oncogene 1<\/td>\nAkt|PKB|PKB\/Akt|PKBalpha|Rac<\/td>\n<\/tr>\n
Cav1<\/a><\/td>\ncaveolin 1, caveolae protein<\/td>\nCav|Cav-1<\/td>\n<\/tr>\n
Cav2<\/a><\/td>\ncaveolin 2<\/td>\nAI447843<\/td>\n<\/tr>\n
Ccnd1<\/a><\/td>\ncyclin D1<\/td>\nAI327039|Cyl-1|PRAD1|bcl-1|cD1<\/td>\n<\/tr>\n
Chek1<\/a><\/td>\ncheckpoint kinase 1 homolog (S. pombe)<\/td>\nC85740|Chk1|rad27<\/td>\n<\/tr>\n
Chek2<\/a><\/td>\nCHK2 checkpoint homolog (S. pombe)<\/td>\nCHK2|Cds1|HUCDS1|Rad53<\/td>\n<\/tr>\n
Egfr<\/a><\/td>\nepidermal growth factor receptor<\/td>\n9030024J15Rik|AI552599|Erbb|Errp|Wa5|wa-2|wa2<\/td>\n<\/tr>\n
Egr1<\/a><\/td>\nearly growth response 1<\/td>\nA530045N19Rik|ETR103|Egr-1|Krox-1|Krox-24|Krox24|NGF1-A|NGFI-A|NGFIA|TIS8|Zenk|Zfp-6|Zif268|egr<\/td>\n<\/tr>\n
Erbb2<\/a><\/td>\nv-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro\/glioblastoma derived oncogene homolog (avian)<\/td>\nErbb-2|HER-2|HER2|Neu|c-erbB2|c-neu|mKIAA3023<\/td>\n<\/tr>\n
Mdm2<\/a><\/td>\ntransformed mouse 3T3 cell double minute 2<\/td>\n1700007J15Rik|AA415488|Mdm-2<\/td>\n<\/tr>\n
Myc<\/a><\/td>\nmyelocytomatosis oncogene<\/td>\nAU016757|Myc2|Niard|Nird|bHLHe39<\/td>\n<\/tr>\n
Plk1<\/a><\/td>\npolo-like kinase 1 (Drosophila)<\/td>\nPlk|STPK13<\/td>\n<\/tr>\n
Rb1<\/a><\/td>\nretinoblastoma 1<\/td>\nRb|Rb-1|pRb<\/td>\n<\/tr>\n
Stat1<\/a><\/td>\nsignal transducer and activator of transcription 1<\/td>\n2010005J02Rik|AA408197<\/td>\n<\/tr>\n
Stat3<\/a><\/td>\nsignal transducer and activator of transcription 3<\/td>\n1110034C02Rik|AW109958|Aprf<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Other resources<\/h3>\n\n\n\n\n
Locus<\/th>\nRDB no.<\/th>\nExternal DB<\/th>\nName of Clone<\/th>\nRunningTitle<\/th>\nType<\/th>\n<\/tr>\n
APCS<\/td>\n1820<\/a><\/td>\n<\/td>\nPorcine serum amyloid P component<\/td>\nPorcine serum amyloid P component cDNA<\/td>\nDNA clone<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

(T.M. Aug, 2008)<\/p>\n<\/div>\n

\"\"go to Head<\/a><\/p>\n

\n

<\/a><\/p>\n

\n

Page top<\/a> | Reporter clone<\/a> | p53 status<\/a> | p53 mutant<\/a><\/p>\n<\/div>\n

Renilla Luciferase<\/h3>\n\n\n\n\n\n\n\n\n\n\n
RDB no.<\/th>\nhuman promoter<\/th>\nHeLa<\/th>\nHepG2<\/th>\nB16<\/th>\nMCF-7<\/th>\nC2C12<\/th>\nC2C12+DM<\/th>\nLNCaP<\/th>\nLNCaP+dex<\/th>\nSaos-2<\/th>\nSaos-2serum starvation<\/th>\n293<\/th>\nK562<\/th>\nK562 +TPA<\/th>\nNIH3T3<\/th>\np53 over-expression in HepG2<\/th>\n<\/tr>\n
5507<\/a><\/td>\np53<\/td>\n–<\/td>\n+++<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n
5529<\/a><\/td>\np73 tumor protein<\/td>\n–<\/td>\n–<\/td>\n<\/td>\n<\/td>\n–<\/td>\n<\/td>\n<\/td>\n<\/td>\n–<\/td>\n–<\/td>\n<\/td>\n<\/td>\n<\/td>\n+<\/td>\n
5479<\/a><\/td>\ncollagenase type IV<\/td>\n–<\/td>\n+++<\/td>\n+<\/td>\n–<\/td>\n+<\/td>\n–<\/td>\n<\/td>\n<\/td>\n–<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n+++<\/td>\n
5485<\/a><\/td>\nearly growth response protein 1<\/td>\n–<\/td>\n+++<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n++<\/td>\n<\/td>\n<\/td>\n+++<\/td>\n+++<\/td>\n<\/td>\n
5534<\/a><\/td>\ntelomerase reverse transcriptase,catalytic subunit<\/td>\n–<\/td>\n+<\/td>\n<\/td>\n–<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n–<\/td>\n<\/td>\n–<\/td>\n<\/td>\n<\/td>\n<\/td>\n
5910<\/a><\/td>\nproatate-specific antigen\/kallikrein 3<\/td>\n+<\/td>\n–<\/td>\n+<\/td>\n–<\/td>\n<\/td>\n<\/td>\n+<\/td>\n+<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n
5546<\/a><\/td>\nproatate-specific antigen\/kallikrein 3<\/td>\n–<\/td>\n+<\/td>\n–<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n